← Eichor
Condition: Autoimmune Diseases Of The Nervous System Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Autoimmune Diseases Of The Nervous System

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281Foot Muscles Training in Sclerosis
NA · 1 location(s) · Inés Llamas-Ramos · NCT06665607A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 2 · 20 location(s) · Takeda · NCT06798012Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT06494228Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Phase N/A · 1 location(s) · Children's National Research Institute · NCT04833465RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome
NA · 1 location(s) · Centro de Reabilitacao do Norte · NCT05461898Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
Phase N/A · 76 location(s) · University of Leeds · NCT04102930Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
NA · 1 location(s) · University of Michigan · NCT07392879A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg)
Phase 3 · 129 location(s) · Sanofi · NCT06290141Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480Skeletal Muscle Aging and Responsiveness in Aged People With MS
NA · 1 location(s) · Oklahoma Medical Research Foundation · NCT07500727Lorraine Registry of Multiple Sclerosis
Phase N/A · 1 location(s) · Central Hospital, Nancy, France · NCT02883335Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NA · 1 location(s) · Cionic, Inc. · NCT05964829A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection
Phase 2 · 39 location(s) · TG Therapeutics, Inc. · NCT07503873A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcuta
Phase 1 · 12 location(s) · Hoffmann-La Roche · NCT07667322Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Phase 2 · 17 location(s) · Jena University Hospital · NCT03993262Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment
Phase N/A · 3 location(s) · Azienda Usl di Bologna · NCT06321588Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
NA · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06079294Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Phase N/A · 12 location(s) · AstraZeneca · NCT06909253A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Dose Response of Exercise for Arthritis Management
NA · 1 location(s) · University of South Carolina · NCT06880653IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
Phase 2 · 1 location(s) · Endeavor Health · NCT04153422Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07313462Home Based Infusions for Ocrelizumab
Phase 4 · 1 location(s) · University of Colorado, Denver · NCT04650321Exploring the Gut-Brain Axis in Ageing and Neurodegeneration
Phase N/A · 3 location(s) · IRCCS San Camillo, Venezia, Italy · NCT05934188Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Phase 4 · 1 location(s) · Northwestern University · NCT07225361Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Phase N/A · 1 location(s) · University of Bonn · NCT06460142Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Phase N/A · 23 location(s) · argenx · NCT07264426Lupus Landmark Study: A Prospective Registry and Biorepository
Phase N/A · 25 location(s) · Lupus Research Alliance · NCT05934149
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.